Preclinical development of SGN-CD47M: Protease-activated antibody technology enables selective tumor targeting of the innate immune checkpoint receptor CD47.
Levengood MR, Carosino CM, Zhang X, Lucas S, Ortiz DJ, Westendorf L, Chin AP, Martin AD, Wong A, Hengel SM, Sun H, Zeng W, Yumul R, Dominguez MM, Chen Y, Zheng JH, Karlsson CAB, Trang VH, Senter PD, Gardai SJ.
Levengood MR, et al. Among authors: zheng jh.
Mol Cancer Ther. 2024 Oct 28. doi: 10.1158/1535-7163.MCT-24-0371. Online ahead of print.
Mol Cancer Ther. 2024.
PMID: 39463068